Article Text

other Versions

PDF
Troponins: (Re)defining their limits
  1. James O Baker,
  2. Johannes Reinhold,
  3. Simon Redwood,
  4. Michael S Marber
  1. King's College London BHF Centre, The Rayne Institute, St Thomas' Hospital, London, UK
  1. Correspondence to Professor Michael Marber, The Rayne Institute, 4th Floor Lambeth Wing, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK; mike.marber{at}kcl.ac.uk

Abstract

The diagnosis of myocardial infarction (MI) depends on a rise and/or fall of cardiac biomarkers such as troponins in the appropriate clinical context. Conventional troponin assays lack sensitivity and precision at the low serum concentrations observed in the early hours after the onset of chest pain. New, highly sensitive troponin assays may offer improved certainty in these early hours. Many of these assays can detect troponins reliably at serum concentrations that occur in patients with chronic stable heart disease and even in asymptomatic healthy individuals. Indiscriminate use of these previously undetectable concentrations for the early diagnosis of acute MI will be accompanied by reduced specificity. However, they are likely to improve risk stratification of patients with chronic heart disease. This review focuses on the available highly sensitive troponin assays and their likely use in the diagnosis of acute MI and risk stratification of patients with heart disease.

  • Acute coronary syndrome
  • biomarkers
  • contractile proteins
  • diagnostic tests
  • delivery of care
  • ischaemic heart disease
  • NSTEMI
  • risk stratification
  • routine
  • syndrome
  • troponin

Statistics from Altmetric.com

Footnotes

  • Funding This study received financial support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust and a Medical Research Council DPFS award G1000737.

  • Competing interests MSM is named as an inventor on a patent held by King's College London relating to biomarkers of myocardial infarction.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.